Multiplexed engineering and precision gene editing in cellular immunotherapy

Authors

Alexander Biederstädt
Gohar Shahwar Manzar
May Daher

Publication Date

1-1-2022

Journal

Frontiers in Immunology

Abstract

The advent of cellular immunotherapy in the clinic has entirely redrawn the treatment landscape for a growing number of human cancers. Genetically reprogrammed immune cells, including chimeric antigen receptor (CAR)-modified immune effector cells as well as T cell receptor (TCR) therapy, have demonstrated remarkable responses across different hard-to-treat patient populations. While these novel treatment options have had tremendous success in providing long-term remissions for a considerable fraction of treated patients, a number of challenges remain. Limited

Keywords

cell engineering, gene editing, immune effector cell, cell therapy, CAR (chimeric antigen receptor), CRISPR screening

Comments

PMID: 36483551

DOI

10.3389/fimmu.2022.1063303

PMID

36483551

PMCID

PMC9723254

PubMedCentral® Posted Date

November 2022

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes